Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Xavier Masramón"'
Autor:
Adelaide A. Hebert, MD, Theodore Rosen, MD, Núria Albareda López, BS, Ilonka Zsolt, MD, PhD, Xavier Masramon
Publikováno v:
International Journal of Women's Dermatology, Vol 6, Iss 2, Pp 109-115 (2020)
Background: Ozenoxacin is a topical antibiotic approved in the United States for treatment of impetigo in adults and children age ≥2 months. This analysis evaluated the efficacy and safety of ozenoxacin in specific pediatric age groups. Methods: Da
Externí odkaz:
https://doaj.org/article/ac0ce70512e54d93a9be7c44aefc7a84
Autor:
Stephen Winchester, Alex Castellarnau, Kashif Jabbar, Meera Nadir, Kapila Ranasinghe, Xavier Masramon, George R. Kinghorn, Isaac John, Jeremy R. A. Paull
Publikováno v:
Pharmaceutics, Vol 16, Iss 9, p 1173 (2024)
Background/Objectives: Dendrimer-based astodrimer sodium nasal spray was assessed for its ability to reduce SARS-CoV-2 load in outpatients with COVID-19, which remains a severe illness for vulnerable groups. Methods: This was a randomised, double-bli
Externí odkaz:
https://doaj.org/article/8328b88d31f24c06a1dcb7cc099e0bf0
Publikováno v:
Clinical Drug Investigation. 32:401-412
Background: It has been suggested that peripheral neuropathic pain (PNP) may affect up to 3% of the general population. PNP has a substantial negative impact on patient functioning and quality of life, including reduced productivity and increased con
Publikováno v:
Pain Practice. 12:382-393
Purpose: To analyze the changes in pain severity and associated costs resulting from resource utilization and reduced productivity in patients with gabapentin-refractory peripheral neuropathic pain who switched to pregabalin therapy in primary care s
Autor:
Virginia Morillo, Ana Mañas, María Luisa Gonzálvez, Xavier Masramón, V. López-Gómez, Juan Pablo Ciria, María Carmen Fernández, Maria Pérez
Publikováno v:
Clinical and Translational Oncology. 13:656-663
A previous study of cancer-related neuropathic pain (NP) found that a 10-fold increase in pregabalin (PGB) use increased patients' satisfaction with treatment. Further research of PGB vs. non-pregabalin (non-PGB) treatment was carried out to assess i
Autor:
Xavier Masramón, Félix Ceberio-Balda, María Pérez, Carles Morera-Domínguez, Mariano Flórez-García
Publikováno v:
Pain Practice. 11:369-380
Background: The study aims to prospectively analyze the effect of adding pregabalin upon costs and consequences in the treatment of refractory neck pain under routine medical practice. Methods: A secondary analysis was carried out including patients
Autor:
Vicente Iváñez, María Pérez, Jerónimo Sancho, Albert Molins, Xavier Masramón, Vanessa López Gómez
Publikováno v:
Epilepsy & Behavior. 19:409-413
This 6-month observational, prospective, multicenter study assessed the influence of changes in seizure severity on quality of life in patients with refractory partial epilepsy. Patients (N = 262) diagnosed with partial epilepsy and receiving two ant
Publikováno v:
Clinical Therapeutics. 32:1357-1370
Background: Pregabalin and gabapentin are marketed to treat peripheral neuropathic pain, but head-to-head comparison is lacking. Objectives: The aims of this work were to compare the effects of pregabalin and gabapentin on different patient-reported
Publikováno v:
Rheumatology International
The objective of this study was to evaluate the effect of pregabalin in painful cervical or lumbosacral radiculopathy treated in Primary Care settings under routine clinical practice. An observational, prospective 12-week secondary analysis was carri
Autor:
Juan Cosín Aguilar, Amparo Hernándiz Martínez, Luis Rodríguez Padial, Xavier Masramón Morell, Beatriz Armada Peláez, Rosa Arístegui Urrestarazu, Amparo Aguilar Llopis, José Luis Zamorano Gómez
Publikováno v:
Medicina Clínica. 129:641-645
Fundamento y objetivo La obesidad es un factor de riesgo mayor e independiente para enfermedad cardiovascular. Hemos estudiado la distribucion del sobrepeso y la obesidad en una muestra de pacientes hipertensos de Espana (estudio CORONARIA), los fact